Back to search
Leukemia, Myelogenous, Chronic
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Leukemia, Myelogenous, Chronic trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Leukemia, Myelogenous, Chronic trials you may qualify forBackground: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the c…
Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the can…
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.
The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with…
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patient…
This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increase…
The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplast…
Natural killer (NK) cells are white blood cells that have a limited ability to kill cancer cells. This ability might be enhanced if they are given 24 hours afte…
This phase II trial tests the safety, best dose, and effectiveness of ropeginterferon alfa-2b for the treatment of patients with myelodysplastic syndrome/myelop…